A RANDOmZED, OPEN-LABEL STUDY OF THE ANTIVIRAL EFFICACV ANDSAFETY OF ATAZANAVIR, IN COMBINATION WITH RITONAVIR ORSAQUINAVIR, AND THE COMBINATION OF LOPINAVIR/RITONAVIR EACHWITH TENOFOVIR AND A NUCLEOSIDE IN SUBJECTS WHO HAVEEXPERIENCED VIROLOGIC FAILURE

Not Applicable

• Conditions: -B20 Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases; Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases; B20

• Registration Number: PER-011-02
• Lead Sponsor: BRISTOL MYERS SQUIBB PERU S.A.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2002-01-14
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

The patients must have HIV infection, have not responded to 2 or more previous antiretroviral treatments that in total must have included medicines of all approved classes (IP, INNTI, INTI), have a plasma HIV RNA load of> 1,000 c / mL (Roche Amplicor®) and a CD4 cell count of> 50 cells / mm3.

Exclusion Criteria

Subjects will be excluded from the study if they have previously used (> 30 days) atazanavir, SQV, TFV or lopinavir / ritonavir.

Study & Design

• Study Type: Interventional
• Study Design: Not specified